The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

The Plaza Accord was a 1985 agreement among the G-5 nations—France, Germany, the United States, the United Kingdom, and Japan—to manipulate exchange rates by depreciating the U.S. dollar ...

PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...

Accord BioPharma receives US FDA approval for Imuldosa, a biosimilar to Stelara to treat chronic inflammatory conditions: Our Bureau, Mumbai Monday, October 14, 2024, 16:45 Hrs [I ...

Accord BioPharma has received FDA approval for IMULDOSA, a biosimilar to STELARA, for treating chronic inflammatory conditions like psoriasis and Crohn's disease. Scheduled for a 2025 launch, it aims ...

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) ...

The news comes following the FDA acceptance of the biologics license application (BLA) submitted by Accord BioPharma, a wholly-owned subsidiary of Intas Pharmaceuticals, in October 2023. Imuldosa is a ...

The 420 mg strength of Hercessi, a biosimilar to Herceptin, is used to treat HER2-overexpressing breast and gastric or ...